Please login to the form below

Not currently logged in
Email:
Password:

Biomunex appoints scientific and strategic advisors

Dr Sebastian Amigorena and Dr Dragan Grabulovski

Biomunex Dr Sebastian AmigorenaParis, France-based immuno-oncology specialist Biomunex Pharmaceuticals has appointed Dr Sebastian Amigorena and Dr Dragan Grabulovski as key scientific advisor and key strategic advisor, respectively.

Dr Amigorena (pictured right) is currently a research director at Le Centre National de la Recherché Scientifique (CNRS) and is director of the Inserm Immunity and Cancer Unit at the Institut Curie in Paris.

In his role as scientific advisory, he will help the company to leverage its 'Plug-and-Play' antibody platform for the development of Biomunex's immunotherapeutics pipeline.

Biomunex Dr Dragan GrabulovskiMeanwhile, Dr Grabulovski (pictured left) is a pharmaceutical biotechnology advisor at Grabulovski Consulting Services, having previously served as chief scientific officer of Covagen, which he co-founded.

Prior to Covagen's sales to Johnson & Johnson in 2014, Dr Grabulovski was responsible for the Swiss biotech's research and development strategy, including its Fynomer technology.

Dr Pierre-Emmanuel Gerard, chief executive officer at Biomunex, said: “We are very pleased to welcome Dr Amigorena and Dr Grabulovski as key advisors.

“As international key opinion leaders they will play an instrumental role as we advance our first oncology programmes into pre-clinical and clinical development."

22nd December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics